Jaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025

Reuters

2025/08/14

Jaguar Health Inc. Reports 35% Increase in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025

Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi®, Gelclair®, and Canalevia®-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060956) on August 14, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559495423"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559495423\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559495423?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559495423","market":"nz","top_or_hot":-1,"title":"Jaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Inc. Reports 35% Increase in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi®, Gelclair®, and Canalevia®-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060956) on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-14 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Inc. Reports 35% Increase in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi®, Gelclair®, and Canalevia®-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060956) on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAGX","symbol_name":"Jaguar Animal Health, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL6T7wX3:1","article_id":"2559495423","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559495423","pubTimestamp":1755172874,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi, Gelclair, and Canalevia-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc."},"translate_title":"捷豹健康公司。报告2025年第二季度收入增长35%，处方药净收入较2025年第一季度增长36%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":0.9},"content_text":"Jaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025\n    \n\n        Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi®, Gelclair®, and Canalevia®-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060956) on August 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}